Nasdaq:US$32.06 (-0.11) | HKEX:HK$49.85 (-0.60) | AIM:£4.71 (+0)
Search
EN
简
繁
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
What We Do
Overview
Research and Development
Commercialization in China
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Publications
News & Press Releases
Scientific Publications
Mailing List Sign-up
Shareholder Information
Overview
Announcements
Events, Presentations & Circulars
Share Price & Chart
Major Shareholders
Financial Reports & Filings
Analyst Coverage
Listing FAQs for Shareholders
Information for Shareholders
Corporate Governance
Careers
About Us
Overview
Corporate Information
Board of Directors
Senior Management
Contact Us
What We Do
Overview
Research and Development
Commercialization in China
Other Ventures
Key Corporate Partnerships
Pipeline & Products
Overview
Our Products
Our Pipeline
Expanded Access
News & Publications
News & Press Releases
Scientific Publications
Mailing List Sign-up
Shareholder Information
Overview
Announcements
Events, Presentations & Circulars
Share Price & Chart
Major Shareholders
Financial Reports & Filings
Analyst Coverage
Listing FAQs for Shareholders
Information for Shareholders
Corporate Governance
Careers
News & Presentations
Hutchmed
| News & Presentations
News & Press Releases
29 Sep 2021
HUTCHMED Highlights Oral Presentations at 2021 Chinese Society of Clinical Oncology Annual Meeting
Read more
29 Sep 2021
HUTCHMED Announces Closing of Divestment of Non-Core OTC Joint Venture
Read more
21 Sep 2021
HUTCHMED Initiates SURTORI-01, a Phase III Trial of SULANDA® in Combination with TUOYI® in the Treatment of Advanced Neuroendocrine Carcinoma in China
Read more
20 Sep 2021
HUTCHMED Initiates a Japan Bridging Study to Support Surufatinib Registration for Advanced Neuroendocrine Tumors
Read more
Scientific Publications
17 Sep 2021
ESMO2021: A Phase Ib/II Study of Fruquintinib in Combination with Tislelizumab in Patients with Advanced Triple Negative Breast Cancer
Read more
22 Jun 2021
The Lancet Respiratory Medicine: Savolitinib in Chinese NSCLC patients harbouring MET exon 14 skipping alterations
Read more
4 Jun 2021
ASCO 2021: An Open-Label Phase 1b/2 Study of Surufatinib in Combination with Tislelizumab in Patients with Advanced Solid Tumors
Read more
4 Jun 2021
ASCO 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors (NETs)
Read more
Mailing List Sign-up
If you would like to be kept up to date with the latest news of HUTCHMED, please sign up to our mailing list . We will deliver the relevant material directly to your email box as soon as it becomes available online.